Acura and Catalent Team Up for LTX-03 Advancement
The companies have engaged in a manufacturing scale-up of LTX-03 tablets for clinical testing using LIMITx Technology.
Acura Pharmaceuticals announced it has initiated a manufacturing scale-up of LTX-03 (hydrocodone bitartrate and acetaminophen) tablets for clinical testing with Catalent Pharma Solutions.
According to a Sept. 9, 2019 press release, the tablets use LIMITx Technology, which is designed to obstruct the release of active drug ingredients when too many tablets are ingested by neutralizing stomach acid with buffer ingredients. The technology also delivers efficacious amounts of the drug when taken as a single tablet with a nominal buffer dose.
Four clinical studies of formulations using the technology have already been completed and showed proof-of-concept and have identified the key components of its formulation for advancement to formal clinical testing.
The formulation and manufacturing process optimization process for LTX-03 tablets is currently nearing completion.
Source: Acura Pharmaceuticals
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
